Titre The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
Protocole ID RADICALPC
ClinicalTrials.gov ID NCT03127631
Type(s) de cancer Prostate
Phase Autres
Institution CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
   HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
      3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2
Ville Montréal
Investigateur(trice) principal(e) Dr Tamim Niazi
Coordonnateur(trice) Kelli Dimayuga
 514-340-8222 poste 21285
Statut Actif en recrutement
Critètes d'éligibilité A man with a diagnosis of prostate cancer that is either:
  • new (i.e. the diagnosis was made within 1 year of the baseline visit) or
  • treated with Androgen Deprivation Therapy for the first time within 1 month prior to the baseline visit, or
  • to be treated with Androgen Deprivation Therapy for the first time within 1 month after the baseline visit
Critètes d'exclusion
  • Unwilling to provide consent, or
  • Are <45 years of age
  • Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they:
    • see a cardiologist every year, or
    • are undertaking all of the following:
      • aspirin use, and
      • statin use, and
      • ACE-I use, and
      • exercise 4 or more times per week